Finch Therapeutics Group, Inc. Share Price
Equities
FNCH
US31773D2009
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.24 USD | -2.61% | -19.68% | -37.95% |
03-25 | Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-12 | Top Premarket Decliners | MT |
Sales 2022 | 861K 69M | Sales 2023 | 107K 8.58M | Capitalization | 5.8M 465M |
---|---|---|---|---|---|
Net income 2022 | -115M -9.22B | Net income 2023 | -74M -5.93B | EV / Sales 2022 | 5.01 x |
Net cash position 2022 | 18.68M 1.5B | Net Debt 2023 | 5M 401M | EV / Sales 2023 | 101 x |
P/E ratio 2022 |
-0.2
x | P/E ratio 2023 |
-0.08
x | Employees | 1 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 46.52% |
1 day | -2.61% | ||
1 week | -19.68% | ||
1 month | -13.85% | ||
3 months | -18.55% | ||
6 months | -42.27% | ||
Current year | -37.95% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Blischak
CEO | Chief Executive Officer | - | 15/05/23 |
Lance Thibault
DFI | Director of Finance/CFO | 58 | 15/05/23 |
Sonia Timberlake
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Susan Graf
CHM | Chairman | 52 | 22/04/21 |
Jeffery Smisek
BRD | Director/Board Member | 69 | 31/08/17 |
Chris W. Shumway
BRD | Director/Board Member | 58 | 31/08/20 |
Date | Price | Change | Volume |
---|---|---|---|
30/04/24 | 2.24 | -2.61% | 15,680 |
29/04/24 | 2.3 | -0.86% | 39,285 |
26/04/24 | 2.32 | +3.57% | 38,235 |
25/04/24 | 2.24 | -2.61% | 41,721 |
24/04/24 | 2.3 | -17.53% | 118,273 |
Delayed Quote Nasdaq, April 30, 2024 at 09:30 pm
More quotes1st Jan change | Capi. | |
---|---|---|
-37.95% | 3.6M | |
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |
- Stock Market
- Equities
- FNCH Stock